查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1836370

2032 年脂质体阿霉素市场预测：按产品类型、分销管道、应用、最终用户和地区进行的全球分析

Liposomal Doxorubicin Market Forecasts to 2032 - Global Analysis By Product Type (Doxil / Caelyx, Myocet, Lipodox, and Other Liposomal Formulations), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球脂质体阿霉素市场预计在 2025 年达到 14.2 亿美元，预计到 2032 年将达到 26.1 亿美元，预测期内的复合年增长率为 9.0%。

脂质体阿霉素是阿霉素的升级版，其设计将药物包裹在脂质体中，以提高疗效和安全性。这种剂型延长了药物在血液中的停留时间，并最大限度地减少了不良副作用，尤其是心臟毒性。脂质体在卵巢癌、乳癌、多发性骨髓瘤和卡波西氏肉瘤的治疗中扮演重要角色。脂质体阿霉素提供标靶药物输送，与传统阿霉素相比，其疗效更高。

根据剑桥大学估计，到2040年，全球乳癌患者数预计将达到300多万人。

对标靶有效化疗的需求不断增加

对精准医疗的日益重视推动了对脂质体阿霉素作为标靶化疗的需求。脂质体能够将细胞毒药物直接输送到癌细胞，同时最大限度地减少全身暴露，这正在彻底改变癌症治疗通讯协定。奈米技术和脂质体药物传输系统的进步正在提高治疗效果并减少副作用。随着全球癌症发生率的上升，医疗保健提供者越来越多地采用脂质体製剂来改善患者的治疗效果。人工智慧在癌症诊断中的整合也支援个人化化疗方案。总之，这些因素促成了脂质体阿霉素在现代癌症治疗中的广泛应用。

製造流程复杂且高成本

生产脂质体阿霉素需要复杂的配方技术和严格的品管措施，导致成本高且技术负担沉重。保持粒径均匀性和包封率需要专门的设备和熟练的人员。遵守GMP和FDA指南等标准会增加额外的复杂性和成本。人们正在探索连续生产和自动化等新技术以简化生产流程，但其应用仍然有限。小型製造商在扩大业务方面面临挑战，因为高昂的资本投入和先进设备的有限取得。这些障碍可能会减缓市场扩张并限制产品供应。

联合治疗开发

人们对联合治疗日益增长的兴趣为脂质体阿霉素与免疫疗法、标靶药物和放射线治疗的联合应用提供了重要机会。这种多重药物联合治疗有望提高治疗效果并克服抗药性。生物标记主导的治疗选择方面的创新使得能够根据个别患者情况制定更精确的联合方案。临床试验越来越多地探索脂质体阿霉素与查核点和激酶抑制剂的协同作用。伴随诊断的兴起促进了患者分层和治疗优化。随着肿瘤学向综合治疗模式发展，脂质体阿霉素将在组合方案中发挥核心作用。

可能的副作用和毒性

儘管脂质体阿霉素具有标靶递送功能，但仍可能引起心臟毒性、手足症候群和骨髓抑制等副作用。这些风险可能会限制其在某些患者群体中的使用，尤其是那些已有潜在疾病的患者。正在进行的研究致力于改进脂质体製剂，以提高其安全性并减少脱靶效应。聚合物奈米颗粒和抗体药物复合体等替代药物递送平台的出现构成了竞争威胁。关于长期毒性和上市后监测的监管审查也日益严格。如果不在製剂和病患监测方面持续创新，安全问题可能会减缓市场成长。

COVID-19的影响：

新冠疫情扰乱了癌症治疗途径，延误了许多癌症患者的诊断和治疗时间。供应链中断影响了脂质体阿霉素和其他化疗药物的供应。然而，这场危机加速了远端医疗和远端患者监护的普及，重塑了癌症治疗的模式。监管机构已实施紧急通讯协定，以确保治疗的连续性，包括加速关键药物的核准。疫情后的復苏正促使市场对韧性製造和去中心化分销模式进行再投资。这些转变预计将增强脂质体阿霉素市场的适应性和长期成长前景。

预计乳癌将成为预测期内最大的癌症类别

由于乳癌在全球的高发病率和完善的治疗方案，预计该领域将在预测期内占据最大的市场份额。脂质体阿霉素广泛用于治疗转移性和復发性乳癌，与传统製剂相比，其耐受性更高。影像学和分子分析技术的进步使得更早发现和更有针对性的治疗成为可能。目前，临床指引建议有心臟风险因子的患者使用脂质体製剂，进一步加速了其应用。正在进行的临床试验正在评估荷尔蒙疗法和HER2标靶治疗联合治疗的疗效。这些进展巩固了乳癌治疗在市场上的主导地位。

预计居家照护领域在预测期内将实现最高复合年增长率

预计在预测期内，居家医疗领域将呈现最高成长率，这得益于癌症治疗向门诊和自行给药的转变。脂质体阿霉素良好的安全性和较低的住院需求使其非常适合家庭治疗模式。穿戴式输液设备和远端监控技术的创新正在提高患者的便利性和依从性。医疗保健系统正在推广分散式医疗，以降低成本并改善医疗可近性，尤其是在农村和服务不足地区。报销框架正在不断发展，以支持家庭化疗的发展。

占比最高的地区

预计亚太地区将在预测期内占据最大的市场份额，这得益于癌症发病率的上升和医疗基础设施的不断扩张。中国、印度和日本等国家正大力投资肿瘤学研究和国内製药生产。政府正透过补贴和加速核准倡议鼓励采用先进的治疗方法。该地区的临床试验以及全球和本地製药公司之间的合作正在活性化。人工智慧诊断和远距肿瘤学平台等技术的采用正在加速治疗的可及性。

复合年增长率最高的地区：

在预测期内，北美预计将见证最高的复合年增长率，这得益于强劲的研发投入和创新癌症疗法的早期应用。美国和加拿大在开发下一代脂质体製剂和组合方案处于领先地位。监管机构正在简化突破性抗癌药物的核准途径，提高市场弹性。医院和癌症中心越来越多地采用数位化工具来制定个人化治疗方案和追踪患者。优惠的报销政策和较高的认知度正在推动对先进化疗方案的需求。随着精准肿瘤学的发展势头强劲，北美将继续成为全球市场成长的标竿。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球脂质体阿霉素市场（依产品类型）

  • Doxil/凯利克斯
  • Mio 套装
  • 脂质体
  • 其他脂质体製剂

6. 全球脂质体阿霉素市场依分销管道划分

  • 医院药房
  • 网路药局
  • 零售药局

7. 全球脂质体阿霉素市场（依应用）

  • 乳癌
  • 卵巢癌
  • 子宫内膜癌
  • 卡波西氏肉瘤
  • 多发性骨髓瘤
  • 白血病
  • 肾癌
  • 骨癌
  • 其他的

8. 全球脂质体阿霉素市场（以最终用户划分）

  • 医院
  • 专科诊所
  • 居家照护
  • 其他的

9. 全球脂质体阿霉素市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Johnson & Johnson
  • Sandoz
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Cadila
  • Pfizer Inc.
  • Intas Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Formosa Laboratories, Inc.
  • Celsion Corporation
  • Pacira BioSciences, Inc.
  • Gilead Sciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eagle Pharmaceuticals, Inc.
  • Ligand Pharmaceuticals
Product Code: SMRC31494

According to Stratistics MRC, the Global Liposomal Doxorubicin Market is accounted for $1.42 billion in 2025 and is expected to reach $2.61 billion by 2032 growing at a CAGR of 9.0% during the forecast period. Liposomal doxorubicin is an advanced version of doxorubicin, designed by enclosing the drug in liposomes for improved efficacy and safety. This formulation prolongs the drug's presence in the bloodstream and minimizes harmful side effects, especially cardiotoxicity. Commonly prescribed in oncology, it plays an important role in treating conditions such as ovarian cancer, breast cancer, multiple myeloma, and Kaposi's sarcoma. By offering targeted drug delivery, liposomal doxorubicin provides enhanced therapeutic benefits compared to conventional doxorubicin.

According to Cambridge University estimates, the global number of breast cancer cases is expected to reach over 3 million by 2040.

Market Dynamics:

Driver:

Rising demand for targeted & effective chemotherapy

The growing emphasis on precision medicine is fueling demand for liposomal doxorubicin as a targeted chemotherapy option. Its ability to deliver cytotoxic agents directly to tumor cells while minimizing systemic exposure is revolutionizing cancer treatment protocols. Advancements in nanotechnology and lipid-based drug delivery systems are enhancing therapeutic efficacy and reducing adverse effects. As cancer prevalence rises globally, healthcare providers are increasingly adopting liposomal formulations for improved patient outcomes. The integration of AI in oncology diagnostics is also supporting personalized chemotherapy regimens. These factors collectively contribute to the expanding footprint of liposomal doxorubicin in modern cancer care.

Restraint:

Complex and high-cost manufacturing process

The production of liposomal doxorubicin involves intricate formulation techniques and stringent quality control measures, making it both costly and technically demanding. Specialized equipment and skilled personnel are required to maintain particle size uniformity and encapsulation efficiency. Regulatory compliance with standards like GMP and FDA guidelines adds further complexity and expense. Emerging technologies such as continuous manufacturing and automation are being explored to streamline production, but adoption remains limited. Smaller manufacturers face challenges in scaling operations due to high capital investment and limited access to advanced facilities. These hurdles can slow market expansion and restrict product availability.

Opportunity:

Development of combination therapies

The growing interest in combination therapies presents a significant opportunity for liposomal doxorubicin to be paired with immunotherapies, targeted agents, or radiation. Such multi-modal approaches are showing promise in enhancing treatment efficacy and overcoming drug resistance. Innovations in biomarker-driven therapy selection are enabling more precise combinations tailored to individual patient profiles. Clinical trials are increasingly exploring synergistic effects between liposomal doxorubicin and checkpoint inhibitors or kinase inhibitors. The rise of companion diagnostics is facilitating better patient stratification and therapy optimization. As oncology moves toward integrated treatment models, liposomal doxorubicin is poised to play a central role in combination regimens.

Threat:

Potential side effects and toxicity

Despite its targeted delivery, liposomal doxorubicin can still cause adverse effects such as cardiotoxicity, hand-foot syndrome, and myelosuppression. These risks may limit its use in certain patient populations, especially those with pre-existing conditions. Ongoing research is focused on refining liposomal formulations to improve safety profiles and reduce off-target effects. The emergence of alternative drug delivery platforms, such as polymeric nanoparticles and antibody-drug conjugates, poses competitive threats. Regulatory scrutiny around long-term toxicity and post-marketing surveillance is intensifying. Without continued innovation in formulation and patient monitoring, safety concerns could dampen market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted oncology care pathways, delaying diagnoses and treatment schedules for many cancer patients. Supply chain interruptions affected the availability of liposomal doxorubicin and other chemotherapy agents. However, the crisis accelerated the adoption of telemedicine and remote patient monitoring, reshaping cancer care delivery. Regulatory bodies introduced emergency protocols to ensure continuity of treatment, including fast-tracked approvals for critical drugs. Post-pandemic recovery is driving renewed investment in resilient manufacturing and decentralized distribution models. These shifts are expected to strengthen the liposomal doxorubicin market's adaptability and long-term growth prospects.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to account for the largest market share during the forecast period, due to its high global incidence and established treatment protocols. Liposomal doxorubicin is widely used in metastatic and recurrent breast cancer cases, offering improved tolerability over conventional formulations. Technological advancements in imaging and molecular profiling are enabling earlier detection and more targeted therapy. Clinical guidelines increasingly recommend liposomal formulations for patients with cardiac risk factors, further boosting adoption. Ongoing trials are evaluating its efficacy in combination with hormonal and HER2-targeted therapies. These developments reinforce breast cancer's leading position in the market.

The homecare segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare segment is predicted to witness the highest growth rate, driven by the shift toward outpatient and self-administered cancer therapies. Liposomal doxorubicin's favorable safety profile and reduced hospitalization needs make it suitable for home-based treatment models. Innovations in wearable infusion devices and remote monitoring technologies are enhancing patient convenience and adherence. Healthcare systems are promoting decentralized care to reduce costs and improve access, especially in rural and underserved areas. Reimbursement frameworks are evolving to support home-based chemotherapy delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by rising cancer prevalence and expanding healthcare infrastructure. Countries like China, India, and Japan are investing heavily in oncology research and domestic drug manufacturing. Government initiatives are encouraging the adoption of advanced therapies through subsidies and fast-track approvals. The region is witnessing increased clinical trial activity and partnerships between global pharma firms and local players. Technological adoption, including AI-driven diagnostics and tele-oncology platforms, is accelerating treatment access.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fueled by robust R&D investment and early adoption of innovative cancer therapies. The U.S. and Canada are at the forefront of developing next-generation liposomal formulations and combination regimens. Regulatory agencies are streamlining approval pathways for breakthrough oncology drugs, enhancing market agility. Hospitals and cancer centers are integrating digital tools for personalized treatment planning and patient tracking. Favorable reimbursement policies and high awareness levels are driving demand for advanced chemotherapy options. As precision oncology gains momentum, North America continues to set the benchmark for global market growth.

Key players in the market

Some of the key players in Liposomal Doxorubicin Market include Johnson & Johnson, Sandoz, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Pfizer Inc., Intas Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Formosa Laboratories, Inc., Celsion Corporation, Pacira BioSciences, Inc., Gilead Sciences, Inc., Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Eagle Pharmaceuticals, Inc., and Ligand Pharmaceuticals.

Key Developments:

In September 2025, The Johnson & Johnson (J&J) announced a $5 million investment in the Africa Frontline First (AFF) Catalytic Fund, a fund hosted by the Global Fund to Fight AIDS, TB & Malaria. As an AFF Catalytic Fund founding supporter, the J&J Foundation's total pledge has now increased to a total of $20 million for the training and deployment of 200,000 professional community health workers (CHWs) into national health systems across Africa.

In May 2025, Sun Pharmaceutical Industries Limited announced the completion of its acquisition of Checkpoint Therapeutics, Inc., an immunotherapy and targeted Oncology Company. As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDAapproved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.

Product Types Covered:

  • Doxil / Caelyx
  • Myocet
  • Lipodox
  • Other Liposomal Formulations
  • Other Product Types

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Breast Cancer
  • Ovarian Cancer
  • Endometrial Cancer
  • Kaposi Sarcoma
  • Multiple Myeloma
  • Leukemia
  • Kidney Cancer
  • Bone Sarcoma
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Liposomal Doxorubicin Market, By Product Type

  • 5.1 Introduction
  • 5.2 Doxil / Caelyx
  • 5.3 Myocet
  • 5.4 Lipodox
  • 5.5 Other Liposomal Formulations

6 Global Liposomal Doxorubicin Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Hospital Pharmacies
  • 6.3 Online Pharmacies
  • 6.4 Retail Pharmacies

7 Global Liposomal Doxorubicin Market, By Application

  • 7.1 Introduction
  • 7.2 Breast Cancer
  • 7.3 Ovarian Cancer
  • 7.4 Endometrial Cancer
  • 7.5 Kaposi Sarcoma
  • 7.6 Multiple Myeloma
  • 7.7 Leukemia
  • 7.8 Kidney Cancer
  • 7.9 Bone Sarcoma
  • 7.10 Other Applications

8 Global Liposomal Doxorubicin Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Homecare
  • 8.5 Other End Users

9 Global Liposomal Doxorubicin Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Johnson & Johnson
  • 11.2 Sandoz
  • 11.3 Sun Pharmaceutical Industries Ltd.
  • 11.4 Zydus Cadila
  • 11.5 Pfizer Inc.
  • 11.6 Intas Pharmaceuticals Ltd.
  • 11.7 Teva Pharmaceutical Industries Ltd.
  • 11.8 Formosa Laboratories, Inc.
  • 11.9 Celsion Corporation
  • 11.10 Pacira BioSciences, Inc.
  • 11.11 Gilead Sciences, Inc.
  • 11.12 Dr. Reddy's Laboratories Ltd.
  • 11.13 Eisai Co., Ltd.
  • 11.14 Eagle Pharmaceuticals, Inc.
  • 11.15 Ligand Pharmaceuticals

List of Tables

  • Table 1 Global Liposomal Doxorubicin Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Liposomal Doxorubicin Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Liposomal Doxorubicin Market Outlook, By Doxil / Caelyx (2024-2032) ($MN)
  • Table 4 Global Liposomal Doxorubicin Market Outlook, By Myocet (2024-2032) ($MN)
  • Table 5 Global Liposomal Doxorubicin Market Outlook, By Lipodox (2024-2032) ($MN)
  • Table 6 Global Liposomal Doxorubicin Market Outlook, By Other Liposomal Formulations (2024-2032) ($MN)
  • Table 7 Global Liposomal Doxorubicin Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 8 Global Liposomal Doxorubicin Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 9 Global Liposomal Doxorubicin Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 10 Global Liposomal Doxorubicin Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 11 Global Liposomal Doxorubicin Market Outlook, By Application (2024-2032) ($MN)
  • Table 12 Global Liposomal Doxorubicin Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 13 Global Liposomal Doxorubicin Market Outlook, By Ovarian Cancer (2024-2032) ($MN)
  • Table 14 Global Liposomal Doxorubicin Market Outlook, By Endometrial Cancer (2024-2032) ($MN)
  • Table 15 Global Liposomal Doxorubicin Market Outlook, By Kaposi Sarcoma (2024-2032) ($MN)
  • Table 16 Global Liposomal Doxorubicin Market Outlook, By Multiple Myeloma (2024-2032) ($MN)
  • Table 17 Global Liposomal Doxorubicin Market Outlook, By Leukemia (2024-2032) ($MN)
  • Table 18 Global Liposomal Doxorubicin Market Outlook, By Kidney Cancer (2024-2032) ($MN)
  • Table 19 Global Liposomal Doxorubicin Market Outlook, By Bone Sarcoma (2024-2032) ($MN)
  • Table 20 Global Liposomal Doxorubicin Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 21 Global Liposomal Doxorubicin Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Liposomal Doxorubicin Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 23 Global Liposomal Doxorubicin Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 24 Global Liposomal Doxorubicin Market Outlook, By Homecare (2024-2032) ($MN)
  • Table 25 Global Liposomal Doxorubicin Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.